Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311755009> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4311755009 abstract "Abstract Background Directly Observed Treatment Short Course for Tuberculosis (TB) (DOTS) treatment currently produces a cure rate of 80%. Rifampicin (RMP) and isoniazid (INH) are the main bactericides; both show wide inter-individual pharmacokinetics and narrow therapeutic range. Therapeutic drug monitoring (TDM) of antiTB drugs is a strategy to improve the response to treatment. The aim of this work was to optimize and individualize antiTB treatment based on plasma concentrations of RMP and INH, NAT2 genotyping and the Bayesian estimation of PK parameters. Methods A prospective and analytical study including TB patients under DOTS scheme was performed. Venous blood samples were drawn 2 and 4 hours after last dose; INH and RMP were quantified by liquid chromatography coupled to tandem mass spectrometry. Anthropometric and clinical information was retrieved from medical records. Acetylator phenotype was determined based on NAT2 genotyping by real-time PCR. Bayesian estimation of the PK parameters was performed using NONMEM and dosing scheme was proposed to achieve therapeutic concentrations of RIF and INH. Results A total 62 patients were included from 18 to 80 years and 35 to 117 kg of total body weight. The most frequent was pulmonary infection (40%), 25% of patients had type 2 diabetes mellitus and 58.5% were slow acetylators for the NAT2 gene. Lower INH and RMP plasma concentrations were related to adverse clinical outcome, compared to those patients classified with early clinical success [1.9 vs 3.7 mg/L and 16.9 vs 10.0 mg/L (p< 0.05)]. Results indicate the need to adjust anti-TB drugs dose to more than 50% of the patients who show plasma concentrations outside the range for both drugs. Bayesian dosing performed was validated after individualization by quantification and interpretation of INH and RMP plasma concentrations followed by a narrow medical follow up. Conclusion Even with standard anti-TB treatment, great proportion of patients show subtherapeutic concentrations of RMP and INH which is associated with overall therapeutic failure. TDM is a useful tool to individualize antimicrobials dose and improve clinical outcomes at early stages of active TB. Disclosures All Authors: No reported disclosures." @default.
- W4311755009 created "2022-12-28" @default.
- W4311755009 creator A5007908535 @default.
- W4311755009 creator A5019961857 @default.
- W4311755009 creator A5027504212 @default.
- W4311755009 creator A5040087881 @default.
- W4311755009 creator A5048372993 @default.
- W4311755009 creator A5050864965 @default.
- W4311755009 creator A5058112895 @default.
- W4311755009 creator A5090055624 @default.
- W4311755009 date "2022-12-01" @default.
- W4311755009 modified "2023-09-26" @default.
- W4311755009 title "1449. Therapeutic Drug Monitoring of Isoniazid and Rifampicin and Clinical Outcomes in Adults with Tuberculosis." @default.
- W4311755009 doi "https://doi.org/10.1093/ofid/ofac492.1276" @default.
- W4311755009 hasPublicationYear "2022" @default.
- W4311755009 type Work @default.
- W4311755009 citedByCount "0" @default.
- W4311755009 crossrefType "journal-article" @default.
- W4311755009 hasAuthorship W4311755009A5007908535 @default.
- W4311755009 hasAuthorship W4311755009A5019961857 @default.
- W4311755009 hasAuthorship W4311755009A5027504212 @default.
- W4311755009 hasAuthorship W4311755009A5040087881 @default.
- W4311755009 hasAuthorship W4311755009A5048372993 @default.
- W4311755009 hasAuthorship W4311755009A5050864965 @default.
- W4311755009 hasAuthorship W4311755009A5058112895 @default.
- W4311755009 hasAuthorship W4311755009A5090055624 @default.
- W4311755009 hasBestOaLocation W43117550091 @default.
- W4311755009 hasConcept C104317684 @default.
- W4311755009 hasConcept C112705442 @default.
- W4311755009 hasConcept C126322002 @default.
- W4311755009 hasConcept C135763542 @default.
- W4311755009 hasConcept C142724271 @default.
- W4311755009 hasConcept C185592680 @default.
- W4311755009 hasConcept C197934379 @default.
- W4311755009 hasConcept C19831878 @default.
- W4311755009 hasConcept C2776967927 @default.
- W4311755009 hasConcept C2777288759 @default.
- W4311755009 hasConcept C2778607973 @default.
- W4311755009 hasConcept C2780035454 @default.
- W4311755009 hasConcept C2780272996 @default.
- W4311755009 hasConcept C2781069245 @default.
- W4311755009 hasConcept C31467283 @default.
- W4311755009 hasConcept C55493867 @default.
- W4311755009 hasConcept C71924100 @default.
- W4311755009 hasConcept C98274493 @default.
- W4311755009 hasConceptScore W4311755009C104317684 @default.
- W4311755009 hasConceptScore W4311755009C112705442 @default.
- W4311755009 hasConceptScore W4311755009C126322002 @default.
- W4311755009 hasConceptScore W4311755009C135763542 @default.
- W4311755009 hasConceptScore W4311755009C142724271 @default.
- W4311755009 hasConceptScore W4311755009C185592680 @default.
- W4311755009 hasConceptScore W4311755009C197934379 @default.
- W4311755009 hasConceptScore W4311755009C19831878 @default.
- W4311755009 hasConceptScore W4311755009C2776967927 @default.
- W4311755009 hasConceptScore W4311755009C2777288759 @default.
- W4311755009 hasConceptScore W4311755009C2778607973 @default.
- W4311755009 hasConceptScore W4311755009C2780035454 @default.
- W4311755009 hasConceptScore W4311755009C2780272996 @default.
- W4311755009 hasConceptScore W4311755009C2781069245 @default.
- W4311755009 hasConceptScore W4311755009C31467283 @default.
- W4311755009 hasConceptScore W4311755009C55493867 @default.
- W4311755009 hasConceptScore W4311755009C71924100 @default.
- W4311755009 hasConceptScore W4311755009C98274493 @default.
- W4311755009 hasIssue "Supplement_2" @default.
- W4311755009 hasLocation W43117550091 @default.
- W4311755009 hasOpenAccess W4311755009 @default.
- W4311755009 hasPrimaryLocation W43117550091 @default.
- W4311755009 hasRelatedWork W1964074490 @default.
- W4311755009 hasRelatedWork W1964500934 @default.
- W4311755009 hasRelatedWork W2004325424 @default.
- W4311755009 hasRelatedWork W2008329752 @default.
- W4311755009 hasRelatedWork W2075070071 @default.
- W4311755009 hasRelatedWork W2418948164 @default.
- W4311755009 hasRelatedWork W2420918848 @default.
- W4311755009 hasRelatedWork W2468058800 @default.
- W4311755009 hasRelatedWork W3205238027 @default.
- W4311755009 hasRelatedWork W588357882 @default.
- W4311755009 hasVolume "9" @default.
- W4311755009 isParatext "false" @default.
- W4311755009 isRetracted "false" @default.
- W4311755009 workType "article" @default.